GGrantIndex
← Leaderboards

Irina V Balyasnikova

University Of Chicago

$8,101,877
Attributed
$12,111,317
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY201425
$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,111,317 · 9

By mechanism

R01$10,139,180 · 6
R21$1,577,334 · 2
R33$394,803 · 1

Top collaborators

Most similar at University Of Chicago

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoCellsGliomaGlioblastomaTumorBrainAntibodiesBrain NeoplasmsIn VitroAnimalsImagePre-ClinicalAdultSolid NeoplasmImmunotherapyT-LymphocyteMalignant NeoplasmsTissuesInfiltrationEngineeringFlow CytometrySpecificityMediatingNeoplastic Cell

Grant awards (26)

Spatial and Temporal Tracking of Neural Stem Cells Migration to Brain Metastases of Breast Cancer using High Resolution Imaging$696,133
R01 · FY2025 · CA · contact PI
Targeting SEC61 complex to overcome resistance to immunotherapy in GBM$577,634
R01 · FY2025 · CA · contact PI
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive Glioblastoma$529,375
R01 · FY2025 · CA
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM$348,526
R01 · FY2025 · NS · contact PI
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive Glioblastoma$533,757
R01 · FY2024 · CA
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM$381,961
R01 · FY2024 · NS · contact PI
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive Glioblastoma$563,302
R01 · FY2023 · CA
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM$393,773
R01 · FY2023 · NS · contact PI
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive Glioblastoma$588,673
R01 · FY2022 · CA
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$520,925
R01 · FY2022 · NS · contact PI
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM$408,013
R01 · FY2022 · NS · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$524,691
R01 · FY2021 · NS · contact PI
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM$413,641
R01 · FY2021 · NS · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$527,915
R01 · FY2020 · NS · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$531,045
R01 · FY2019 · NS · contact PI
Neural Stem Cell Carriers for Glioblastoma Immunotherapy$394,803
R33 · FY2019 · NS · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$548,582
R01 · FY2018 · NS · contact PI
Intranasal Stem-Cell Based Therapy for Glioblastoma$399,501
R01 · FY2018 · NS · contact PI
Neural Stem Cell Carriers for Glioblastoma Immunotherapy$385,694
R21 · FY2018 · NS · contact PI
Intranasal Stem-Cell Based Therapy for Glioblastoma$405,762
R01 · FY2017 · NS
Neural Stem Cell Carriers for Glioblastoma Immunotherapy$388,890
R21 · FY2017 · NS · contact PI
Intranasal Stem-Cell Based Therapy for Glioblastoma$407,515
R01 · FY2016 · NS
Intranasal Stem-Cell Based Therapy for Glioblastoma$419,228
R01 · FY2015 · NS
IL13Ra2 targeted T-cell therapy for glioma$394,125
R21 · FY2015 · NS · contact PI
Intranasal Stem-Cell Based Therapy for Glioblastoma$419,228
R01 · FY2014 · NS
IL13Ra2 targeted T-cell therapy for glioma$408,625
R21 · FY2014 · NS · contact PI